Patient-reported outcomes in a phase 3, randomized, open-label study evaluating the efficacy of axicabtagene ciloleucel (axi-cel) versus standard of care therapy in patients with relapsed/refractory large b-cell lymphoma (ZUMA-7)
Authors
Elsawy, M.Chavez, J. C.
Avivi, I.
Larouche, J. F.
Wannesson, L.
Cwynarski, K.
Osman, K.
Davison, K.
Rudzki, J. D.
Dahiya, S.
Dorritie, K.
Jaglowski, S.
Radford, John A
Morschhauser, F.
Cunningham, D.
Garcia-Sancho, A. M.
Tzachanis, D.
Ulrickson, M. L.
Karmali, R.
Kekre, N.
Thieblemont, C.
Enblad, G.
Dreger, P.
Malladi, R.
Joshi, N.
Wang, W. J.
Solem, C. T.
Snider, J. T.
To, C.
Kersten, M. J.
Affiliation
Queen Elizabeth II Health Sciences Centre and Dalhouse University, Halifax, CanadaIssue Date
2021
Metadata
Show full item recordCitation
Elsawy M, Chavez JC, Avivi I, Larouche JF, Wannesson L, Cwynarski K, et al. Patient-Reported Outcomes in a Phase 3, Randomized, Open-Label Study Evaluating the Efficacy of Axicabtagene Ciloleucel (Axi-Cel) Versus Standard of Care Therapy in Patients with Relapsed/Refractory Large B-Cell Lymphoma (ZUMA-7). Blood. 2021 Nov;138. PubMed PMID: WOS:000736398801204.Journal
BloodDOI
10.1182/blood-2021-147598Additional Links
https://dx.doi.org/10.1182/blood-2021-147598Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1182/blood-2021-147598